Life Sciences Firms’ Use Of At-The-Market Financing Vehicle Rising
This article was originally published in The Pink Sheet Daily
ATM transactions by U.S. life sciences firms totaled $90 million in the first quarter of 2012, says Brinson Patrick, the highest volume since the investment bank began tracking such financings in 1999.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.